MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

ESPERION THERAPEUTICS INC

Deschisă

SectorSănătate

0.88 3.53

Rezumat

Modificarea prețului

24h

Curent

Minim

0.85

Maxim

0.89

Indicatori cheie

By Trading Economics

Venit

8.2M

-21M

Vânzări

17M

69M

EPS

-0.101

Marjă de profit

-30.845

Angajați

304

EBITDA

9.5M

-4.9M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+638.64% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-166M

169M

Deschiderea anterioară

-2.65

Închiderea anterioară

0.88

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

ESPERION THERAPEUTICS INC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2025, 23:54 UTC

Acțiuni populare

Stocks to Watch: Alphabet, Intel, AppFolio

24 apr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 apr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 apr. 2025, 23:37 UTC

Top știri

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 apr. 2025, 23:36 UTC

Top știri

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 apr. 2025, 23:13 UTC

Top știri
Câștiguri

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 apr. 2025, 23:09 UTC

Top știri

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 apr. 2025, 22:51 UTC

Top știri
Achiziții, Fuziuni, Preluări

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr. 2025, 22:48 UTC

Top știri

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 apr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 apr. 2025, 22:38 UTC

Market Talk
Câștiguri

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 apr. 2025, 22:24 UTC

Câștiguri

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 apr. 2025, 22:24 UTC

Câștiguri

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 apr. 2025, 22:24 UTC

Market Talk
Câștiguri

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 apr. 2025, 22:23 UTC

Câștiguri

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 apr. 2025, 22:11 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

24 apr. 2025, 22:11 UTC

Market Talk
Câștiguri

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 apr. 2025, 22:09 UTC

Top știri
Câștiguri

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 apr. 2025, 22:00 UTC

Market Talk
Câștiguri

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 apr. 2025, 21:39 UTC

Top știri

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 apr. 2025, 21:23 UTC

Top știri
Câștiguri

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 apr. 2025, 21:04 UTC

Câștiguri

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 apr. 2025, 21:03 UTC

Câștiguri

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 apr. 2025, 21:03 UTC

Câștiguri

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 apr. 2025, 21:02 UTC

Câștiguri

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparație

Modificare preț

ESPERION THERAPEUTICS INC Așteptări

Obiectiv de preț

By TipRanks

638.64% sus

Prognoză pe 12 luni

Medie 6.5 USD  638.64%

Maxim 16 USD

Minim 2 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruESPERION THERAPEUTICS INC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

6 ratings

4

Cumpărare

1

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

0.8191 / 0.95Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.